Centivax Closes $37 Million Financing to Accelerate Phase 2 Clinical Development of Universal Flu and Advance Follow-On Portfolio to Clinical Readiness
On March 30, 2026, a biotechnology company named Centivax, Inc. based in South San Francisco completed a funding round that exceeded expectations by securing $37 million. The company focuses on developing vaccines and therapies aimed at providing long-lasting and universal defense against a wide range of targets.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments